Jubilant Pharmova’s board of directors has approved plans to separate the active pharmaceutical ingredients business of its generic pharmaceuticals subsidiary, Jubilant Generics Limited, and take control of it on a going concern basis.
The planned reorganization would enable common management and “presence across the value chain” for both generic and innovative APIs within the firm’s contract research organization and contract development and manufacturing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?